-+ 0.00%
-+ 0.00%
-+ 0.00%

Cardiol expands US MAVERIC Phase III recurrent pericarditis trial network to 25 sites

PUBT·04/28/2026 11:29:26
Listen to the news
Cardiol expands US MAVERIC Phase III recurrent pericarditis trial network to 25 sites
  • Cardiol Therapeutics expanded its U.S. site network for MAVERIC, its pivotal Phase III trial of CardiolRx for prevention of recurrence in recurrent pericarditis.
  • Enrollment reached 75%, supporting planned activation of up to seven additional U.S. centers and a total of about 25 sites.
  • Target recruitment is expected by end of Q2 2026, with timing potentially extending into Q3 to accommodate added sites.
  • Trial builds on Phase II results already presented at American Heart Association Scientific Sessions 2024, which showed sustained symptom and inflammation improvement with fewer recurrences.
  • Company positioned MAVERIC as an NDA-enabling program intended to support a U.S. FDA filing for a non-immunosuppressive oral therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiol Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: TO44668) on April 28, 2026, and is solely responsible for the information contained therein.